Citations

Citations to this article as recorded by  

• Aldo-keto reductase (AKR) superfamily website and database: An update
  Andrea Andress Huacachino, Jaehyun Joo, Nisha Narayanan, Anisha Tehim, Blanca E. Himes, Trevor M. Penning
  Chemico-Biological Interactions.2024; 398: 111111.     CrossRef

Citations

Citations to this article as recorded by  

• A Novel Score Based on Controlled Attenuation Parameter Accurately Predicts Hepatic Steatosis in Individuals With Metabolic Dysfunction Associated Steatotic Liver Disease: A Derivation and Independent Validation Study
  Zi-Ming An, Qiao-Hong Liu, Xin-Jian Ye, Qian Zhang, Hua-Fu Pei, Xin Xin, Jie Yuan, Qian Huang, Kun Liu, Fang Lu, Zhi-Han Yan, Yu Zhao, Yi-Yang Hu, Ming-Hua Zheng, Qin Feng
  Clinical and Translational Gastroenterology.2024; 15(3): e00680.     CrossRef
• Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort
  Joo Hyun Oh, Sang Bong Ahn, Seon Cho, Eun-Hee Nah, Eileen L. Yoon, Dae Won Jun
  Journal of Hepatology.2024;[Epub]     CrossRef
• A Composite Blood Biomarker Including AKR1B10 and Cytokeratin 18 for Progressive Types of Nonalcoholic Fatty Liver Disease
  Seung Joon Choi, Sungjin Yoon, Kyoung-Kon Kim, Doojin Kim, Hye Eun Lee, Kwang Gi Kim, Seung Kak Shin, Ie Byung Park, Seong Min Kim, Dae Ho Lee
  Diabetes & Metabolism Journal.2024; 48(4): 740.     CrossRef
• Imaging Methods Applicable in the Diagnostics of Alzheimer’s Disease, Considering the Involvement of Insulin Resistance
  Petra Hnilicova, Ema Kantorova, Stanislav Sutovsky, Milan Grofik, Kamil Zelenak, Egon Kurca, Norbert Zilka, Petra Parvanovova, Martin Kolisek
  International Journal of Molecular Sciences.2023; 24(4): 3325.     CrossRef
• Polyunsaturated and Saturated Oxylipin Plasma Levels Allow Monitoring the Non-Alcoholic Fatty Liver Disease Progression to Severe Stages
  Miguel D. Ferrer, Clara Reynés, Margalida Monserrat-Mesquida, Magdalena Quetglas-Llabrés, Cristina Bouzas, Silvia García, David Mateos, Miguel Casares, Cristina Gómez, Lucía Ugarriza, Josep A. Tur, Antoni Sureda, Antoni Pons
  Antioxidants.2023; 12(3): 711.     CrossRef
• An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography
  Jia-xu Liang, Javier Ampuero, Hao Niu, Kento Imajo, Mazen Noureddin, Jaideep Behari, Dae Ho Lee, Richard L. Ehman, Fredrik Rorsman, Johan Vessby, Juan R. Lacalle, Ferenc E. Mózes, Michael Pavlides, Quentin M. Anstee, Stephen A. Harrison, Javier Castell, R
  Journal of Hepatology.2023; 79(3): 592.     CrossRef
• Relationship between controlled attenuated parameter and magnetic resonance imaging–proton density fat fraction for evaluating hepatic steatosis in patients with NAFLD
  Ziming An, Qiaohong Liu, Wenli Zeng, Yan Wang, Qian Zhang, Huafu Pei, Xin Xin, Shuohui Yang, Fang Lu, Yu Zhao, Yiyang Hu, Qin Feng
  Hepatology Communications.2022; 6(8): 1975.     CrossRef
• Noninvasive imaging of hepatic dysfunction: A state-of-the-art review
  Ting Duan, Han-Yu Jiang, Wen-Wu Ling, Bin Song
  World Journal of Gastroenterology.2022; 28(16): 1625.     CrossRef
• Diagnosis and Pathogenesis of Sarcopenia in Chronic Liver Disease Using Liver Magnetic Resonance Imaging
  Atsushi Nakamura, Tsubasa Yoshimura, Tomomi Sato, Takeshi Ichikawa
  Cureus.2022;[Epub]     CrossRef
• Plasma Aldo-Keto Reductase Family 1 Member B10 as a Biomarker Performs Well in the Diagnosis of Nonalcoholic Steatohepatitis and Fibrosis
  Aron Park, Seung Joon Choi, Sungjin Park, Seong Min Kim, Hye Eun Lee, Minjae Joo, Kyoung Kon Kim, Doojin Kim, Dong Hae Chung, Jae Been Im, Jaehun Jung, Seung Kak Shin, Byung-Chul Oh, Cheolsoo Choi, Seungyoon Nam, Dae Ho Lee
  International Journal of Molecular Sciences.2022; 23(9): 5035.     CrossRef
• Contribution of a genetic risk score to ethnic differences in fatty liver disease
  Maddie J. Kubiliun, Jonathan C. Cohen, Helen H. Hobbs, Julia Kozlitina
  Liver International.2022; 42(10): 2227.     CrossRef
• Plasma Metabolomics and Machine Learning-Driven Novel Diagnostic Signature for Non-Alcoholic Steatohepatitis
  Moongi Ji, Yunju Jo, Seung Joon Choi, Seong Min Kim, Kyoung Kon Kim, Byung-Chul Oh, Dongryeol Ryu, Man-Jeong Paik, Dae Ho Lee
  Biomedicines.2022; 10(7): 1669.     CrossRef
• Updated S2k Clinical Practice Guideline on Non-alcoholic Fatty Liver Disease (NAFLD) issued by the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) – April 2022 – AWMF Registration No.: 021–025
  
  Zeitschrift für Gastroenterologie.2022; 60(09): e733.     CrossRef
• Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025
  E. Roeb, A. Canbay, H. Bantel, J. Bojunga, J. de Laffolie, M. Demir, U. W. Denzer, A. Geier, W. P. Hofmann, C. Hudert, T. Karlas, M. Krawczyk, T. Longerich, T. Luedde, M. Roden, J. Schattenberg, M. Sterneck, A. Tannapfel, P. Lorenz, F. Tacke
  Zeitschrift für Gastroenterologie.2022; 60(09): 1346.     CrossRef
• Ultrasound Methods for the Assessment of Liver Steatosis: A Critical Appraisal
  Dorotea Bozic, Kristian Podrug, Ivana Mikolasevic, Ivica Grgurevic
  Diagnostics.2022; 12(10): 2287.     CrossRef
• Significance of liver fat loss in chronic liver disease: Usefulness of hepatic proton density fat fraction measurement by magnetic resonance imaging in evaluating malnutrition
  Atsushi Nakamura, Haruka Okada, Tsubasa Yoshimura, Manami Deguchi, Yuei Hosokawa, Tomomi Satoh, Takeshi Ichikawa, Keiji Okuyama, Yoshihiro Yoshioka, Hitoshi Asakura
  Kanzo.2021; 62(9): 525.     CrossRef
• Screening for nonalcoholic fatty liver disease-when, who and how?
  Christoph G Dietrich, Monika Rau, Andreas Geier
  World Journal of Gastroenterology.2021; 27(35): 5803.     CrossRef

This clinical practice position statement, a product of the Fatty Liver Research Group of the Korean Diabetes Association, proposes recommendations for the diagnosis, progression and/or severity assessment, management, and follow-up of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM). Patients with both T2DM and NAFLD have an increased risk of non-alcoholic steatohepatitis (NASH) and fibrosis and a higher risk of cardiovascular diseases and diabetic complications compared to those without NAFLD. With regards to the evaluation of patients with T2DM and NAFLD, ultrasonography-based stepwise approaches using noninvasive biomarker models such as fibrosis-4 or the NAFLD fibrosis score as well as imaging studies such as vibration-controlled transient elastography with controlled attenuation parameter or magnetic resonance imaging-proton density fat fraction are recommended. After the diagnosis of NAFLD, the stage of fibrosis needs to be assessed appropriately. For management, weight reduction achieved by lifestyle modification has proven beneficial and is recommended in combination with antidiabetic agent(s). Evidence that some antidiabetic agents improve NAFLD/NASH with fibrosis in patients with T2DM is emerging. However, there are currently no definite pharmacologic treatments for NAFLD in patients with T2DM. For specific cases, bariatric surgery may be an option if indicated.

Citations

Citations to this article as recorded by  

• A combined extract containing Schisandra chinensis (SCE) reduced hepatic triglyceride accumulation in rats fed a high-sucrose diet
  Haneul Lee, Eun Young Kang, Joowon Lee, Yejin Kim, Sumin Kang, Hayoon Kim, Hyun Kyung Kim, Gyoungok Gang, Sang-gil Lee, Cao Lei, Gwang-woong Go
  Food Science and Biotechnology.2024; 33(6): 1449.     CrossRef
• Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
  Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
  BMJ.2024; : e076388.     CrossRef
• Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
  Inha Jung, Dae-Jeong Koo, Won-Young Lee
  Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
• Association between urinary polycyclic aromatic hydrocarbons and risk of metabolic associated fatty liver disease
  Minzhen Wang, Shaoyan Tang, Lulu Zhang, Yamin Zhao, Yindi Peng, Shan zheng, Zanchao Liu
  International Archives of Occupational and Environmental Health.2024; 97(7): 695.     CrossRef
• A Composite Blood Biomarker Including AKR1B10 and Cytokeratin 18 for Progressive Types of Nonalcoholic Fatty Liver Disease
  Seung Joon Choi, Sungjin Yoon, Kyoung-Kon Kim, Doojin Kim, Hye Eun Lee, Kwang Gi Kim, Seung Kak Shin, Ie Byung Park, Seong Min Kim, Dae Ho Lee
  Diabetes & Metabolism Journal.2024; 48(4): 740.     CrossRef
• Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy
  Xi Lu, Qingxing Xie, Xiaohui Pan, Ruining Zhang, Xinyi Zhang, Ge Peng, Yuwei Zhang, Sumin Shen, Nanwei Tong
  Signal Transduction and Targeted Therapy.2024;[Epub]     CrossRef
• Risk Scores for Prediction of Major Cardiovascular Events in Non-Alcoholic Fatty Liver Disease: A No Man’s Land?
  Liliana Gheorghe, Roxana Nemteanu, Andreea Clim, Gina Eosefina Botnariu, Irina Iuliana Costache, Alina Plesa
  Life.2023; 13(4): 857.     CrossRef
• Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis
  Hye Jin Chun, Eun Ran Kim, Minyoung Lee, Da Hyun Choi, Soo Hyun Kim, Eugene Shin, Jin-Hong Kim, Jin Won Cho, Dai Hoon Han, Bong-Soo Cha, Yong-ho Lee
  Metabolism.2023; 145: 155612.     CrossRef
• Association between fatty liver index and risk of end-stage renal disease stratified by kidney function in patients with type 2 diabetes: A nationwide population-based study
  Goh Eun Chung, Kyungdo Han, Kyu-Na Lee, Jung Ho Bae, Sun Young Yang, Su-Yeon Choi, Jeong Yoon Yim, Nam Ju Heo
  Diabetes & Metabolism.2023; 49(4): 101454.     CrossRef
• Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis
  Min Jeong Park, Hayeon Kim, Myeong Gyu Kim, Kyungim Kim
  Clinical and Molecular Hepatology.2023; 29(3): 693.     CrossRef
• Histological analysis of hypoglycemic agents on liver fibrosis in patients with non-alcoholic fatty liver disease: a systematic review
  Qingxing Xie, Xiaohui Pan, Xinyue Zhang, Jinfang Ma, Ge Peng, Nanwei Tong
  Chinese Medical Journal.2023; 136(16): 2014.     CrossRef
• Hepatotropc effects of glucose-lowering drugs: non-alcoholic fatty liver disease in focus
  E. V. Uzhakova, Z. E. Zshanko, E. N. Smirnova
  Experimental and Clinical Gastroenterology.2023; (6): 121.     CrossRef
• Complementary effects of dapagliflozin and lobeglitazone on metabolism in a diet-induced obese mouse model
  Yun Kyung Lee, Tae Jung Oh, Ji In Lee, Bo Yoon Choi, Hyen Chung Cho, Hak Chul Jang, Sung Hee Choi
  European Journal of Pharmacology.2023; 957: 175946.     CrossRef
• Hepatic T-cell senescence and exhaustion are implicated in the progression of fatty liver disease in patients with type 2 diabetes and mouse model with nonalcoholic steatohepatitis
  Byeong Chang Sim, Yea Eun Kang, Sun Kyoung You, Seong Eun Lee, Ha Thi Nga, Ho Yeop Lee, Thi Linh Nguyen, Ji Sun Moon, Jingwen Tian, Hyo Ju Jang, Jeong Eun Lee, Hyon-Seung Yi
  Cell Death & Disease.2023;[Epub]     CrossRef
• 2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
  Jong Han Choi, Kyung Ae Lee, Joon Ho Moon, Suk Chon, Dae Jung Kim, Hyun Jin Kim, Nan Hee Kim, Ji A Seo, Mee Kyoung Kim, Jeong Hyun Lim, YoonJu Song, Ye Seul Yang, Jae Hyeon Kim, You-Bin Lee, Junghyun Noh, Kyu Yeon Hur, Jong Suk Park, Sang Youl Rhee, Hae J
  Diabetes & Metabolism Journal.2023; 47(5): 575.     CrossRef
• Circ_0004535/miR-1827/CASP8 network involved in type 2 diabetes mellitus with nonalcoholic fatty liver disease
  Min Li, Ai Zeng, Xinle Tang, Hui Xu, Wei Xiong, Yanying Guo
  Scientific Reports.2023;[Epub]     CrossRef
• Stratification by obesity class, rather than age, can identify a higher percent of children at risk for non‐alcoholic fatty liver disease and metabolic dysfunction
  Aurelia Radulescu, Adam J. Dugan, Mary Killian, Suzanna L. Attia, Marialena Mouzaki, George J. Fuchs, Rohit Kohli, Henrietta Bada, Philip A. Kern, Samir Softic
  Pediatric Obesity.2022;[Epub]     CrossRef
• Renal Tubular Damage Marker, Urinary N-acetyl-β-D-Glucosaminidase, as a Predictive Marker of Hepatic Fibrosis in Type 2 Diabetes Mellitus
  Hae Kyung Kim, Minyoung Lee, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
  Diabetes & Metabolism Journal.2022; 46(1): 104.     CrossRef
• Dulaglutide Ameliorates Palmitic Acid-Induced Hepatic Steatosis by Activating FAM3A Signaling Pathway
  Jinmi Lee, Seok-Woo Hong, Min-Jeong Kim, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee
  Endocrinology and Metabolism.2022; 37(1): 74.     CrossRef
• State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis
  Yongin Cho, Yong-ho Lee
  Endocrinology and Metabolism.2022; 37(1): 38.     CrossRef
• Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study)
  Yongin Cho, Hyungjin Rhee, Young-eun Kim, Minyoung Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Jin-Young Choi, Yong-ho Lee
  BMC Medicine.2022;[Epub]     CrossRef
• Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease
  Ji Hye Huh, Kwang Joon Kim, Seung Up Kim, Bong-Soo Cha, Byung-Wan Lee
  Hepatobiliary & Pancreatic Diseases International.2022; 21(3): 241.     CrossRef
• Anti-Obesity and Anti-Hyperglycemic Effects of Meretrix lusoria Protamex Hydrolysate in ob/ob Mice
  Min Ju Kim, Ramakrishna Chilakala, Hee Geun Jo, Seung-Jae Lee, Dong-Sung Lee, Sun Hee Cheong
  International Journal of Molecular Sciences.2022; 23(7): 4015.     CrossRef
• The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study
  Jiyun Park, Gyuri Kim, Bong-Sung Kim, Kyung-Do Han, So Yoon Kwon, So Hee Park, You-Bin Lee, Sang-Man Jin, Jae Hyeon Kim
  Cardiovascular Diabetology.2022;[Epub]     CrossRef
• Cumulative Exposure to High γ-Glutamyl Transferase Level and Risk of Diabetes: A Nationwide Population-Based Study
  Ji-Yeon Park, Kyungdo Han, Hun-Sung Kim, Jae-Hyoung Cho, Kun-Ho Yoon, Mee Kyoung Kim, Seung-Hwan Lee
  Endocrinology and Metabolism.2022; 37(2): 272.     CrossRef
• SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease
  Jun Sung Moon, Jun Hwa Hong, Yong Jin Jung, Ele Ferrannini, Michael A. Nauck, Soo Lim
  Trends in Endocrinology & Metabolism.2022; 33(6): 424.     CrossRef
• Plasma Aldo-Keto Reductase Family 1 Member B10 as a Biomarker Performs Well in the Diagnosis of Nonalcoholic Steatohepatitis and Fibrosis
  Aron Park, Seung Joon Choi, Sungjin Park, Seong Min Kim, Hye Eun Lee, Minjae Joo, Kyoung Kon Kim, Doojin Kim, Dong Hae Chung, Jae Been Im, Jaehun Jung, Seung Kak Shin, Byung-Chul Oh, Cheolsoo Choi, Seungyoon Nam, Dae Ho Lee
  International Journal of Molecular Sciences.2022; 23(9): 5035.     CrossRef
• Chinese Herbal Medicine for Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
  Sihan Peng, Lu Liu, Ziyan Xie, Xiyu Zhang, Chunguang Xie, Sha Ye, Xiangeng Zhang, Xiaoli Liang, Hongyan Wang, Ya Liu
  Frontiers in Pharmacology.2022;[Epub]     CrossRef
• Non-alcoholic fatty liver disease and sarcopenia is associated with the risk of albuminuria independent of insulin resistance, and obesity
  Eugene Han, Mi Kyung Kim, Seung-Soon Im, Byoung Kuk Jang, Hye Soon Kim
  Journal of Diabetes and its Complications.2022; 36(8): 108253.     CrossRef
• Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?
  Eun-Jung Rhee
  Endocrinology and Metabolism.2022; 37(3): 415.     CrossRef
• Plasma Metabolomics and Machine Learning-Driven Novel Diagnostic Signature for Non-Alcoholic Steatohepatitis
  Moongi Ji, Yunju Jo, Seung Joon Choi, Seong Min Kim, Kyoung Kon Kim, Byung-Chul Oh, Dongryeol Ryu, Man-Jeong Paik, Dae Ho Lee
  Biomedicines.2022; 10(7): 1669.     CrossRef
• Association Between DPP4 Inhibitor Use and the Incidence of Cirrhosis, ESRD, and Some Cancers in Patients With Diabetes
  Yewon Na, Soo Wan Kim, Ie Byung Park, Soo Jung Choi, Seungyoon Nam, Jaehun Jung, Dae Ho Lee
  The Journal of Clinical Endocrinology & Metabolism.2022; 107(11): 3022.     CrossRef
• Nonalcoholic fatty liver disease is associated with early left ventricular diastolic dysfunction in patients with type 2 diabeteS
  Walaa Sheba, Eman Morsy, Salah Altahan, Mona Ayaad, Sameh A. Lashen
  Alexandria Journal of Medicine.2022; 58(1): 117.     CrossRef
• The association between changes in hepatic steatosis and hepatic fibrosis with cardiovascular outcomes and mortality in patients with New-Onset type 2 Diabetes: A nationwide cohort study
  Jiyun Park, Gyuri Kim, Bong-Sung Kim, Kyung-Do Han, So Yoon Kwon, So Hee Park, You-Bin Lee, Sang-Man Jin, Jae Hyeon Kim
  Diabetes Research and Clinical Practice.2022; 194: 110191.     CrossRef
• Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2022;46:630-9)
  Ji Hye Huh
  Diabetes & Metabolism Journal.2022; 46(6): 953.     CrossRef
• The association of fatty liver index and BARD score with all-cause and cause-specific mortality in patients with type 2 diabetes mellitus: a nationwide population-based study
  Goh Eun Chung, Su-Min Jeong, Eun Ju Cho, Ji Won Yoon, Jeong-Ju Yoo, Yuri Cho, Kyu-na Lee, Dong Wook Shin, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Su Jong Yu
  Cardiovascular Diabetology.2022;[Epub]     CrossRef
• Non-Albumin Proteinuria (NAP) as a Complementary Marker for Diabetic Kidney Disease (DKD)
  Jaehyun Bae, Young Jun Won, Byung-Wan Lee
  Life.2021; 11(3): 224.     CrossRef
• Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: Diagnosis and Treatment
  Sook Jung Lee, Byung-Wan Lee
  The Journal of Korean Diabetes.2021; 22(1): 38.     CrossRef
• Non-alcoholic fatty liver disease
  Elizabeth E Powell, Vincent Wai-Sun Wong, Mary Rinella
  The Lancet.2021; 397(10290): 2212.     CrossRef
• Allopurinol ameliorates high fructose diet induced hepatic steatosis in diabetic rats through modulation of lipid metabolism, inflammation, and ER stress pathway
  In-Jin Cho, Da-Hee Oh, Jin Yoo, You-Cheol Hwang, Kyu Jeung Ahn, Ho-Yeon Chung, Soung Won Jeong, Ju-Young Moon, Sang-Ho Lee, Sung-Jig Lim, In-Kyung Jeong
  Scientific Reports.2021;[Epub]     CrossRef
• Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
  A. E. Bagriy, A. D. Zubov, M. V. Khomenko, E. S. Mikhailichenko, E. A. Pylaeva, N. A. Khaustova, E. V. Bryukhovetskaya
  Russian Journal of Gastroenterology, Hepatology, Coloproctology.2021; 31(2): 14.     CrossRef
• Liver Fibrosis Indices for the Prediction of Mortality in Korean Subjects: A 16-Year Prospective Cohort Study
  Tae Jung Oh, Kyuho Kim, Jae Hoon Moon, Sung Hee Choi, Nam H Cho, Hak Chul Jang
  Journal of the Endocrine Society.2021;[Epub]     CrossRef
• Reduced Rank Regression-Derived Dietary Patterns Related to the Fatty Liver Index and Associations with Type 2 Diabetes Mellitus among Ghanaian Populations under Transition: The RODAM Study
  Tracy Bonsu Osei, Anne-Marieke van Dijk, Sjoerd Dingerink, Felix Patience Chilunga, Erik Beune, Karlijn Anna Catharina Meeks, Silver Bahendeka, Matthias Bernd Schulze, Charles Agyemang, Mary Nicolaou, Adriaan Georgius Holleboom, Ina Danquah
  Nutrients.2021; 13(11): 3679.     CrossRef
• Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
  Yuan Zhu, Jiao Xu, Dong Zhang, Xingyu Mu, Yi Shi, Shangtao Chen, Zengxiang Wu, Shuangqing Li
  Frontiers in Endocrinology.2021;[Epub]     CrossRef
• Liver fibrosis indices are related to diabetic peripheral neuropathy in individuals with type 2 diabetes
  Kyuho Kim, Tae Jung Oh, Hyen Chung Cho, Yun Kyung Lee, Chang Ho Ahn, Bo Kyung Koo, Jae Hoon Moon, Sung Hee Choi, Hak Chul Jang
  Scientific Reports.2021;[Epub]     CrossRef
• Evaluation of Grapefruit Juice in terms of Interleukin 18 Gene Expression in Rats with Fatty Liver and Healthy Rats
  Simin Bahmanpoor, Noosha Zia-Jahromi
  journal of ilam university of medical sciences.2021; 29(4): 74.     CrossRef

Citations

Citations to this article as recorded by  

• Association of statins with nonalcoholic fatty liver disease in patients with diabetes
  Raj Shah, Alexander Kong, Silvio De Melo, Moheb Boktor, Richard Henriquez, Amar Mandalia, Hrishikesh Samant, Carlos A. Alvarez, Ishak A. Mansi
  Journal of Investigative Medicine.2024; 72(6): 497.     CrossRef
• Comparing the Risk of Poor Outcomes Among Hepatitis C–Infected, Cured, and Never-Infected Controls
  Varun Saxena, Weilu Wu, Sreepriya Balasubramanian, Nizar Mukhtar, Suk I. Seo, Joanna B. Ready, Brock A. MacDonald, Julie A. Schmittdiel
  Gastro Hep Advances.2024; 3(6): 871.     CrossRef

Nonalcoholic fatty liver disease (NAFLD) and diabetes are common metabolic disorders that are often comorbid conditions. Among many proposed treatments, weight reduction is the only approved option for NAFLD to date. However, it is not easy to maintain weight loss by lifestyle modification alone; pharmacological treatments are helpful in this regard. Although many drugs have been investigated, pioglitazone could be a first-line therapy in patients with NAFLD and diabetes. Many more drugs are currently being developed and investigated, and it is likely that combination strategies will be used for future treatment of NAFLD and diabetes. Attention should be paid to the management of NAFLD and diabetes and efforts should be made to intervene early and individualize treatment of NAFLD in patients with diabetes.

Citations

Citations to this article as recorded by  

• Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
  Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
  BMJ.2024; : e076388.     CrossRef
• The Efficacy of Empagliflozin in Combination with Pioglitazone on the Improvement of Fatty Liver Disease in Patients with Type 2 Diabetes
  Morteza Aghajanpoor, Mehrzad Gholampourdehaki, Reza Mosaed, Iraj Mirzaii-Dizgah, Afsaneh Vosughi
  Annals of Military and Health Sciences Research.2024;[Epub]     CrossRef
• Research Progress of Traditional Chinese Medicine and Western Medicine on Non-Alcoholic Fatty Liver Disease
  强江 郭
  Advances in Clinical Medicine.2024; 14(03): 561.     CrossRef
• Liver and cardiovascular disease outcomes in metabolic syndrome and diabetic populations: Bi-directional opportunities to multiply preventive strategies
  Alhussain Yasin, Madison Nguyen, Angad Sidhu, Priyanka Majety, Jared Spitz, Amon Asgharpour, Mohammad S. Siddiqui, Laurence S. Sperling, Arshed A. Quyyumi, Anurag Mehta
  Diabetes Research and Clinical Practice.2024; 211: 111650.     CrossRef
• Effect of ipragliflozin on liver enzymes in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
  Rizwana Parveen, Shadan Hussain, Sparsh Saini, Parvej Khan, Nilanjan Saha, Nidhi
  Expert Opinion on Pharmacotherapy.2024; 25(7): 925.     CrossRef
• Effect of aerobic training with silymarin consumption on glycemic indices and liver enzymes in men with type 2 diabetes
  Keyvan Ghalandari, Mojtaba Shabani, Ali Khajehlandi, Amin Mohammadi
  Archives of Physiology and Biochemistry.2023; 129(1): 76.     CrossRef
• Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
  Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
  Diabetes & Metabolism Journal.2023; 47(2): 220.     CrossRef
• Comparative antihypertensive efficacy of combinations of azilsartan medoxomil or olmesartan medoxomil with amlodipine in patients with arterial hypertension, type 2 diabetes mellitus and non-alcoholic fatty liver disease
  I. А. Lukonin, V. V. Skibitsky, A. V. Fendrikova, A. V. Skibitsky, I. A. Antipov
  South Russian Journal of Therapeutic Practice.2023; 4(1): 68.     CrossRef
• An Ethyl Acetate Extract of Eryngium carlinae Inflorescences Attenuates Oxidative Stress and Inflammation in the Liver of Streptozotocin-Induced Diabetic Rats
  Cristian M. Trejo-Hurtado, Cinthia I. Landa-Moreno, Jenaro Lemus-de la Cruz, Donovan J. Peña-Montes, Rocío Montoya-Pérez, Rafael Salgado-Garciglia, Salvador Manzo-Avalos, Christian Cortés-Rojo, Juan Luis Monribot-Villanueva, José Antonio Guerrero-Analco,
  Antioxidants.2023; 12(6): 1235.     CrossRef
• Pharmacogenetics of glucagon-like peptide-1 agonists in the treatment of type 2 diabetes mellitus
  Iu.G. Samoilova, A.E. Stankova, M.V. Matveeva, O.E. Vaizova, D.V. Podchinenova, D.A. Kudlay, T.A. Filippova, I.R. Grishkevich
  Profilakticheskaya meditsina.2023; 26(12): 95.     CrossRef
• Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease
  Ji Hye Huh, Kwang Joon Kim, Seung Up Kim, Bong-Soo Cha, Byung-Wan Lee
  Hepatobiliary & Pancreatic Diseases International.2022; 21(3): 241.     CrossRef
• Triglyceride and glucose index is a simple and easy‐to‐calculate marker associated with nonalcoholic fatty liver disease
  Kyung‐Soo Kim, Sangmo Hong, Hong‐Yup Ahn, Cheol‐Young Park
  Obesity.2022; 30(6): 1279.     CrossRef
• Evaluating Triglyceride and Glucose Index as a Simple and Easy-to-Calculate Marker for All-Cause and Cardiovascular Mortality
  Kyung-Soo Kim, Sangmo Hong, You-Cheol Hwang, Hong-Yup Ahn, Cheol-Young Park
  Journal of General Internal Medicine.2022; 37(16): 4153.     CrossRef
• Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Antidiabetic Agents
  Kyung-Soo Kim
  The Journal of Korean Diabetes.2022; 23(2): 83.     CrossRef
• Efficacy and mechanism of Jiedu Tongluo Tiaogan Formula in treating type 2 diabetes mellitus combined with non-alcoholic fatty liver disease: Study protocol for a parallel-armed, randomized controlled trial
  Jinghan Xu, Chunli Piao, Yue Qu, Tianjiao Liu, Yuting Peng, Qi Li, Xiaohua Zhao, Pei Li, Xuemin Wu, Yawen Fan, Binqin Chen, Jie Yang
  Frontiers in Pharmacology.2022;[Epub]     CrossRef
• Intestinal microbiota in the treatment of metabolically associated fatty liver disease
  Ji-Shuai Wang, Jin-Chun Liu
  World Journal of Clinical Cases.2022; 10(31): 11240.     CrossRef
• Efficiency of combined antihypertensive pharmacotherapy in patients with arterial hypertension, combined with type 2 diabetes mellitus and non-alcoholic fatty liver disease
  I. A. Lukonin, V. V. Skibitsky, A. V. Fendrikova, I. I. Pavlyuchenko, K. Yu. Lazarev, F. A. Kovalenko
  Systemic Hypertension.2022; 19(1): 31.     CrossRef
• Diosgenin Ameliorated Type II Diabetes-Associated Nonalcoholic Fatty Liver Disease through Inhibiting De Novo Lipogenesis and Improving Fatty Acid Oxidation and Mitochondrial Function in Rats
  Yujie Zhong, Zhiman Li, Ruyi Jin, Yanpeng Yao, Silan He, Min Lei, Xin Wang, Chao Shi, Li Gao, Xiaoli Peng
  Nutrients.2022; 14(23): 4994.     CrossRef
• Pluchea indica Leaf Extract Alleviates Dyslipidemia and Hepatic Steatosis by Modifying the Expression of Lipid Metabolism-Related Genes in Rats Fed a High Fat-High Fructose Diet
  Patcharin Singdam, Jarinyaporn Naowaboot, Laddawan Senggunprai, Kampeebhorn Boonloh, Patchareewan Pannangpetch
  Preventive Nutrition and Food Science.2022; 27(4): 384.     CrossRef
• NAFLDin type 2 diabetes mellitus: Still many challenging questions
  Simona Cernea, Itamar Raz
  Diabetes/Metabolism Research and Reviews.2021;[Epub]     CrossRef
• Umbilical Cord-Mesenchymal Stem Cell-Conditioned Medium Improves Insulin Resistance in C2C12 Cell
  Kyung-Soo Kim, Yeon Kyung Choi, Mi Jin Kim, Jung Wook Hwang, Kyunghoon Min, Sang Youn Jung, Soo-Kyung Kim, Yong-Soo Choi, Yong-Wook Cho
  Diabetes & Metabolism Journal.2021; 45(2): 260.     CrossRef
• Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus
  Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
  Diabetes Therapy.2021; 12(1): 171.     CrossRef
• Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: Diagnosis and Treatment
  Sook Jung Lee, Byung-Wan Lee
  The Journal of Korean Diabetes.2021; 22(1): 38.     CrossRef
• Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
  A. E. Bagriy, A. D. Zubov, M. V. Khomenko, E. S. Mikhailichenko, E. A. Pylaeva, N. A. Khaustova, E. V. Bryukhovetskaya
  Russian Journal of Gastroenterology, Hepatology, Coloproctology.2021; 31(2): 14.     CrossRef
• NAFLD and its link with diabetes: Why we should be worried
  Louise Cremonesini, Emma Harkin
  Independent Nurse.2021; 2021(8): 20.     CrossRef
• Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
  Eugene Han, Mi Kyung Kim, Byoung Kuk Jang, Hye Soon Kim
  Diabetes & Metabolism Journal.2021; 45(5): 698.     CrossRef
• Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study
  Jun Hyung Kim, Jin Sil Moon, Seok Joon Byun, Jun Hyeok Lee, Dae Ryong Kang, Ki Chul Sung, Jang Young Kim, Ji Hye Huh
  Cardiovascular Diabetology.2020;[Epub]     CrossRef
• Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial
  Rohit Loomba, Erin Morgan, Lynnetta Watts, Shuting Xia, Lisa A Hannan, Richard S Geary, Brenda F Baker, Sanjay Bhanot
  The Lancet Gastroenterology & Hepatology.2020; 5(9): 829.     CrossRef
• Hepatic fibrosis is associated with total proteinuria in Korean patients with type 2 diabetes
  Eugene Han, Yongin Cho, Kyung-won Kim, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-wan Lee
  Medicine.2020; 99(33): e21038.     CrossRef
• Metabolic liver disease in diabetes – From mechanisms to clinical trials
  Bedair Dewidar, Sabine Kahl, Kalliopi Pafili, Michael Roden
  Metabolism.2020; 111: 154299.     CrossRef
• Managing NAFLD in Type 2 Diabetes: The Effect of Lifestyle Interventions, a Narrative Review
  Siôn A. Parry, Leanne Hodson
  Advances in Therapy.2020; 37(4): 1381.     CrossRef
• Diabetes and Metabolism Journal in 2020: Good to Great
  In-Kyung Jeong
  Diabetes & Metabolism Journal.2020; 44(1): 1.     CrossRef
• Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
  Byung-Wan Lee, Yong-ho Lee, Cheol-Young Park, Eun-Jung Rhee, Won-Young Lee, Nan-Hee Kim, Kyung Mook Choi, Keun-Gyu Park, Yeon-Kyung Choi, Bong-Soo Cha, Dae Ho Lee
  Diabetes & Metabolism Journal.2020; 44(3): 382.     CrossRef
• Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies
  Chang-hua Zhang, Bu-gao Zhou, Jun-qing Sheng, Yang Chen, Ying-qian Cao, Chen Chen
  Pharmacological Research.2020; 159: 104984.     CrossRef
• Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
  Kyung-Soo Kim, Byung-Wan Lee
  Clinical and Molecular Hepatology.2020; 26(4): 430.     CrossRef
• Effects of sodium–glucose cotransporter 2 inhibitors on non‐alcoholic fatty liver disease in patients with type 2 diabetes: A meta‐analysis of randomized controlled trials
  Baodi Xing, Yuhang Zhao, Bingzi Dong, Yue Zhou, Wenshan Lv, Wenjuan Zhao
  Journal of Diabetes Investigation.2020; 11(5): 1238.     CrossRef
• Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress
  Tamiris Ingrid Petito-da-Silva, Vanessa Souza-Mello, Sandra Barbosa-da-Silva
  Molecular and Cellular Endocrinology.2019; 498: 110539.     CrossRef

Nonalcoholic fatty liver disease (NAFLD) and diabetes are common metabolic disorders whose prevalence rates are expected to rise worldwide, corresponding to aging and increasingly obese populations. Compared to the general population (around 25%), 50% to 70% of people with diabetes have NAFLD, and NAFLD severity (including fibrosis) tends to be worsened by the presence of diabetes. NAFLD is considered an emerging risk factor for type 2 diabetes mellitus and a contributor to the development of chronic diabetes-related complications. This reciprocal relationship demonstrates the importance of confirming suspected NAFLD in patients with diabetes. Due to the invasive nature of liver biopsy to assess NAFLD status, various alternative non-invasive modalities have been developed and validated. Here, we summarized the epidemiology of NAFLD in patients with diabetes and reviewed currently available imaging modalities and biomarker-based prediction models for their ability to detect liver steatosis and/or fibrosis.

Citations

Citations to this article as recorded by  

• Recent advances and potentiality of postbiotics in the food industry: Composition, inactivation methods, current applications in metabolic syndrome, and future trends
  Yujie Zhong, Tao Wang, Ruilin Luo, Jiayu Liu, Ruyi Jin, Xiaoli Peng
  Critical Reviews in Food Science and Nutrition.2024; 64(17): 5768.     CrossRef
• Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
  Eugene Han, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Sang Hoon Ahn, Yong-ho Lee, Seung Up Kim
  Metabolism.2024; 152: 155789.     CrossRef
• Intact ketogenesis predicted reduced risk of moderate-severe metabolic-associated fatty liver disease assessed by liver transient elastography in newly diagnosed type 2 diabetes
  Sejeong Lee, Jaehyun Bae, Seung Up Kim, Minyoung Lee, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
  Frontiers in Endocrinology.2024;[Epub]     CrossRef
• ZJU Index as a Predictive Tool for Diabetes Incidence: Insights from a Population-Based Cohort Study
  Chenjiao Wu, Yi Hao Loh, Hangkai Huang, Chengfu Xu
  Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 715.     CrossRef
• Genetically engineered long-acting Esculentin-2CHa(1−30) fusion protein with potential applicability for the treatment of NAFLD
  Jaewoong Lee, Reeju Amatya, Kyung Eun Kim, Young-Hoon Park, Eunmi Hong, Krismala Djayanti, Kyoung Ah Min, Gu Seob Roh, Meong Cheol Shin
  Journal of Controlled Release.2024; 372: 699.     CrossRef
• Sigmoidal relationship between liver fat content and nonalcoholic fatty liver disease in Chinese adults
  Pingping Yu, Huachao Yang, Hu Li, Ying Mei, Yuanyuan Wu, Hongfeng Cheng, Huiru Su, Yueling Deng, Tao Jiang, Zhongxiang He, Peng Hu
  Postgraduate Medical Journal.2024; 100(1186): 562.     CrossRef
• Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study
  Stephen A. Harrison, Juan P. Frias, K. Jean Lucas, Gary Reiss, Guy Neff, Sureka Bollepalli, Yan Su, Doreen Chan, Erik J. Tillman, Ali Moulton, Brittany de Temple, Arian Zari, Reshma Shringarpure, Timothy Rolph, Andrew Cheng, Kitty Yale
  Clinical Gastroenterology and Hepatology.2024;[Epub]     CrossRef
• Association between nonalcoholic fatty liver disease and left ventricular diastolic dysfunction: A 7-year retrospective cohort study of 3,380 adults using serial echocardiography
  Gyuri Kim, Tae Yang Yu, Jae Hwan Jee, Ji Cheol Bae, Mira Kang, Jae Hyeon Kim
  Diabetes & Metabolism.2024; 50(3): 101534.     CrossRef
• Anthropometry, laboratory, and PNPLA3 polymorphisms in a novel model for early identification and evaluation of nonalcoholic fatty liver disease
  Amal A. Mohamed, Rania Al Dweik, Reem A. Abdelghafour, Ahmed Ramadan, Abbas M. Abbas, Hussein H. Samir, Nashwa M. Muharram, Randa Ibrahim Ahmed Elshiha, Naglaa El-Salawy, Doaa Ghaith, Marwa K. Darwish, Soha M. Abd El Salam, Eman A. Sultan, Amina S. Solima
  Informatics in Medicine Unlocked.2024; 48: 101513.     CrossRef
• Relationship between fibrosis-4 score and microvascular complications in patients with type 2 diabetes mellitus
  Beril Turan Erdogan, Abbas Ali Tam, Husniye Baser, Fatma Neslihan Cuhaci Seyrek, Sefika Burcak Polat, Reyhan Ersoy, Oya Topaloglu, Bekir Cakir
  Arab Journal of Gastroenterology.2024; 25(3): 269.     CrossRef
• The relationship between muscle mass and fat content in body composition and non-alcoholic fatty liver disease in the Chinese general population: a cross-sectional study
  Guoqiong Xu, Yuanyuan Wu, Jie Chen, Dan Xiang, Dongji Li
  Frontiers in Medicine.2024;[Epub]     CrossRef
• Noninvasive Liver Fibrosis Indices as Indicators of Microvascular and Macrovascular Complications in Type 2 Diabetes
  Hande Erman, Banu Boyuk, Seyma Arslan, Seydahmet Akin, Özcan Keskin
  Metabolic Syndrome and Related Disorders.2024; 22(8): 619.     CrossRef
• Grading of Fatty Liver Based on Computed Tomography Hounsfield Unit Values versus Ultrasonography Grading
  Sultan Abdulwadoud Alshoabi, Reyan Mohammed Alharbi, Rufaydah Bader Algohani, Shahad Abdullah Alahmadi, Maryam Ahmed, Samah F. Faqeeh, Dalal Alahmadi, Abdulaziz A. Qurashi, Fahad H. Alhazmi, Rakan Mohammed Alrehaili, Abdulrahman Khalil Almughathawi
  Gastroenterology Insights.2024; 15(3): 588.     CrossRef
• Building in vitro models for mechanistic understanding of liver regeneration in chronic liver diseases
  Khushi Karnawat, Rithika Parthasarathy, Mesevilhou Sakhrie, Harikeshav Karthik, Konatala Vibhuvan Krishna, Gowri Manohari Balachander
  Journal of Materials Chemistry B.2024; 12(32): 7669.     CrossRef
• Autophagy alterations in obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease: the evidence from human studies
  Patrycja Jakubek, Barbara Pakula, Martin Rossmeisl, Paolo Pinton, Alessandro Rimessi, Mariusz Roman Wieckowski
  Internal and Emergency Medicine.2024; 19(5): 1473.     CrossRef
• Deploying a metabolic dysfunction-associated steatohepatitis consensus care pathway: findings from an educational pilot in three health systems
  Sonal Kumar, Arpan Mohanty, Parvez Mantry, Robert E. Schwartz, Madeleine Haff, George Therapondos, Mazen Noureddin, Douglas Dieterich, Nigel Girgrah, Kristi Cohn, Mohanish Savanth, Michael Fuchs
  BMC Primary Care.2024;[Epub]     CrossRef
• Efficacy and safety of dapagliflozin add‐on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled study
  In‐Kyung Jeong, Kyung Mook Choi, Kyung Ah Han, Kyoung‐Ah Kim, In Joo Kim, Seung Jin Han, Won Young Lee, Soon Jib Yoo
  Diabetes, Obesity and Metabolism.2024; 26(11): 5065.     CrossRef
• Plasma Adiponectin and Its Correlation with Carotid Intima-Media Thickness in Obesity and in Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
  Maha Hussein, Aasem Saif, Mona Amin, Osama Khalafallah, Ahmed Hussien, Samar Aboulsoud, Shrook Mousa, S. Razzaque Mohammed
  Journal of Nutrition and Metabolism.2023; 2023: 1.     CrossRef
• Exposure to Bisphenol A, S, and F and its Association with Obesity and Diabetes Mellitus in General Adults of Korea: Korean National Environmental Health Survey (KoNEHS) 2015–2017
  Min Kyong Moon, Min Joo Kim, Inae Lee, Sunmi Kim, Sohyeon Choi, Jeongim Park, Yoon Hee Cho, Sooyeon Hong, Jiyoung Yoo, Hyunwoong Park, Gi Jeong Cheon, Young Joo Park, Kyungho Choi
  Exposure and Health.2023; 15(1): 53.     CrossRef
• Liver fat content assessed by conventional B-mode ultrasound and metabolic profile in non-diabetic patients: Implications for clinical practice
  Rosanna Villani, Grazia Pia Magnati, Giulia Tuccari, Moris Sangineto, Antonino Davide Romano, Tommaso Cassano, Gaetano Serviddio
  Ultrasound.2023; 31(3): 177.     CrossRef
• Association of cardiovascular health metrics with annual incidence of prediabetes or diabetes: Analysis of a nationwide real‐world database
  Akira Okada, Hidehiro Kaneko, Satoshi Matsuoka, Hidetaka Itoh, Yuta Suzuki, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Satoko Yamaguchi, Koichi Node, Toshimasa Yamauchi, Hideo Yasunaga, Issei Komuro
  Journal of Diabetes Investigation.2023; 14(3): 452.     CrossRef
• Effects of Environmental Cadmium Exposure on the Liver in Korean Adults: Cross-Sectional and Longitudinal Studies
  Mi-Na Seo, Sang-Yong Eom, Ji-Ae Lim, Jung-Eum Lee, Byung-Sun Choi, Ho-Jang Kwon, Young-Seoub Hong, Heon Kim, Jung-Duck Park
  Archives of Environmental Contamination and Toxicology.2023; 84(2): 237.     CrossRef
• Newer Glucose-Lowering Therapies in Older Adults with Type 2 Diabetes
  Anika Bilal, Richard E. Pratley
  Endocrinology and Metabolism Clinics of North America.2023; 52(2): 355.     CrossRef
• CD24 Gene Expression as a Risk Factor for Non-Alcoholic Fatty Liver Disease
  Mona A. Amin, Halla M. Ragab, Nabila Abd El Maksoud, Wafaa Abd Elaziz
  Diagnostics.2023; 13(5): 984.     CrossRef
• Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
  Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
  Diabetes & Metabolism Journal.2023; 47(2): 220.     CrossRef
• Non-Alcoholic Fatty Liver Disease with Sarcopenia and Carotid Plaque Progression Risk in Patients with Type 2 Diabetes Mellitus
  Yongin Cho, Hye-Sun Park, Byung Wook Huh, Yong-ho Lee, Seong Ha Seo, Da Hea Seo, Seong Hee Ahn, Seongbin Hong, So Hun Kim
  Diabetes & Metabolism Journal.2023; 47(2): 232.     CrossRef
• Nonalcoholic fatty liver disease and type 2 diabetes: an observational and Mendelian randomization study
  Yuetian Yu, Yuefeng Yu, Yuying Wang, Yi Chen, Ningjian Wang, Bin Wang, Yingli Lu
  Frontiers in Endocrinology.2023;[Epub]     CrossRef
• β-sitosterol attenuates high- fat diet-induced hepatic steatosis in rats by modulating lipid metabolism, inflammation and ER stress pathway
  Omayma AR Abo-Zaid, Fatma SM Moawed, Effet Soliman Ismail, Mostafa A. Farrag
  BMC Pharmacology and Toxicology.2023;[Epub]     CrossRef
• Fatty Liver & Diabetes Statistics in Korea: Nationwide Data 2009 to 2017
  Eugene Han, Kyung-Do Han, Yong-ho Lee, Kyung-Soo Kim, Sangmo Hong, Jung Hwan Park, Cheol-Young Park
  Diabetes & Metabolism Journal.2023; 47(3): 347.     CrossRef
• Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis
  Hye Jin Chun, Eun Ran Kim, Minyoung Lee, Da Hyun Choi, Soo Hyun Kim, Eugene Shin, Jin-Hong Kim, Jin Won Cho, Dai Hoon Han, Bong-Soo Cha, Yong-ho Lee
  Metabolism.2023; 145: 155612.     CrossRef
• Role of vascular endothelial growth factor B in nonalcoholic fatty liver disease and its potential value
  Yu-Qi Li, Lei Xin, Yu-Chi Zhao, Shang-Qi Li, Ya-Nuo Li
  World Journal of Hepatology.2023; 15(6): 786.     CrossRef
• Increased risk of incident diabetes in patients with MAFLD not meeting the criteria for NAFLD
  So Hee Park, Jiyun Park, So Yoon Kwon, You-Bin Lee, Gyuri Kim, Kyu Yeon Hur, Janghyun Koh, Jae Hwan Jee, Jae Hyeon Kim, Mira Kang, Sang-Man Jin
  Scientific Reports.2023;[Epub]     CrossRef
• Significance of Diabetic Kidney Disease Biomarkers in Predicting Metabolic-Associated Fatty Liver Disease
  Jaehyun Bae, Byung-Wan Lee
  Biomedicines.2023; 11(7): 1928.     CrossRef
• An Evidence-Based Review of Diabetes Care: History, Types, Relationship to Cancer and Heart Disease, Co-Morbid Factors, and Preventive Measures
  Umesh Chandra Gupta, Subhas Chandra Gupta, Shayle Sugandh Gupta
  Current Nutrition & Food Science.2023; 19(4): 399.     CrossRef
• Associations of serum aminotransferase and the risk of all-cause and cause-specific mortality in Chinese type 2 diabetes: a community-based cohort study
  Jian Su, Haoyu Guan, Xikang Fan, Hao Yu, Yu Qin, Jie Yang, Zheng Zhu, Chong Shen, Enchun Pan, Yan Lu, Jin-Yi Zhou, Ming Wu
  BMJ Open.2023; 13(7): e068160.     CrossRef
• Retinoic acid signaling in fatty liver disease
  Fathima N. Cassim Bawa, Yanqiao Zhang
  Liver Research.2023; 7(3): 189.     CrossRef
• Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy
  Reeju Amatya, Donghee Lee, Kyoung Ah Min, Meong Cheol Shin
  Pharmaceutics.2023; 15(7): 1963.     CrossRef
• Prevalence of Non-Alcoholic Fatty Liver Disease and Its Risk Factors in Korean Population
  Sang Gyeong Lee, Songchan Oh, Moon Seong Kim, Jooyeon Kim, Eunjin Jung, Young Jun Kim, Jiyoun Hong
  Food Supplements and Biomaterials for Health.2023;[Epub]     CrossRef
• Low‑dose ionizing radiation attenuates high glucose‑induced hepatic apoptosis and immune factor release via modulation of a miR‑155‑SOCS1 axis
  Hongqiong Fan, Shanshan Liu, Benzheng Jiao, Xinyue Liang
  Molecular Medicine Reports.2023;[Epub]     CrossRef
• CT-based measurement of visceral adipose tissue volume as a reliable tool for assessing metabolic risk factors in prediabetes across subtypes
  Jihyun Kim, Keunyoung Kim
  Scientific Reports.2023;[Epub]     CrossRef
• The Role of the Fatty Liver Index (FLI) in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review
  Teodora Biciusca, Sorina Ionelia Stan, Mara Amalia Balteanu, Ramona Cioboata, Alice Elena Ghenea, Suzana Danoiu, Ana-Maria Bumbea, Viorel Biciusca
  Diagnostics.2023; 13(21): 3316.     CrossRef
• Circ_0004535/miR-1827/CASP8 network involved in type 2 diabetes mellitus with nonalcoholic fatty liver disease
  Min Li, Ai Zeng, Xinle Tang, Hui Xu, Wei Xiong, Yanying Guo
  Scientific Reports.2023;[Epub]     CrossRef
• Prevalence of High and Moderate Risk of Liver Fibrosis Among Patients With Diabetes at a Noncommunicable Diseases (NCD) Clinic in a Primary Healthcare Center in Northern India
  Anubhav Mondal, Aninda Debnath, Ghurumourthy Dhandapani, Abhishek Sharma, Shveta Lukhmana, Geeta Yadav
  Cureus.2023;[Epub]     CrossRef
• Therapeutic outcome of dapagliflozin on various parameters in non-alcoholic fatty liver disease (NAFLD) patients
  Mazhar Hussain, Muhammad Zafar Majeed Babar, Saba Tariq, Muhammad Irfan Ahmad, Lubna Akhtar
  International Journal of Diabetes in Developing Countries.2022; 42(2): 290.     CrossRef
• Lead, mercury, and cadmium exposures are associated with obesity but not with diabetes mellitus: Korean National Environmental Health Survey (KoNEHS) 2015–2017
  Min Kyong Moon, Inae Lee, Aram Lee, Hyunwoong Park, Min Joo Kim, Sunmi Kim, Yoon Hee Cho, Sooyeon Hong, Jiyoung Yoo, Gi Jeong Cheon, Kyungho Choi, Young Joo Park, Jeongim Park
  Environmental Research.2022; 204: 111888.     CrossRef
• Association of Prenatal Famine Exposure With Inflammatory Markers and Its Impact on Adulthood Liver Function Across Consecutive Generations
  Shiwei Yan, Jingqi Ruan, Yu Wang, Jiaxu Xu, Changhao Sun, Yucun Niu
  Frontiers in Nutrition.2022;[Epub]     CrossRef
• Serum Metabolomics in Patients with Coexisting NAFLD and T2DM Using Liquid Chromatography-Mass Spectrometry
  Cheng Hu, Xiaoyu Zhuang, Jiaqi Zhang, Tao Wang, Shengnan Du, Jinping Wang, Xuelian Peng, Qin Cao, Mingcai Zhang, Yuanye Jiang
  Laboratory Medicine.2022; 53(4): 360.     CrossRef
• Genistein—Opportunities Related to an Interesting Molecule of Natural Origin
  Ewa Garbiec, Judyta Cielecka-Piontek, Magdalena Kowalówka, Magdalena Hołubiec, Przemysław Zalewski
  Molecules.2022; 27(3): 815.     CrossRef
• Renal Tubular Damage Marker, Urinary N-acetyl-β-D-Glucosaminidase, as a Predictive Marker of Hepatic Fibrosis in Type 2 Diabetes Mellitus
  Hae Kyung Kim, Minyoung Lee, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
  Diabetes & Metabolism Journal.2022; 46(1): 104.     CrossRef
• Long-term effects of the changes in hepatic steatosis status on the risk of incident type 2 diabetes mellitus: A 15-year community-based prospective cohort study
  Seung Min Chung, Min Kyu Kang, Jinho Jung, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee, Rohit Loomba, Jung Gil Park, Jun Sung Moon
  Diabetes Research and Clinical Practice.2022; 184: 109208.     CrossRef
• Prevalence and Risk Factors of Advanced Liver Fibrosis in a Population‐Based Study in Germany
  Yvonne Huber, Andreas Schulz, Irene Schmidtmann, Manfred Beutel, Norbert Pfeiffer, Thomas Münzel, Peter R. Galle, Philipp S. Wild, Karl J. Lackner, Jörn M. Schattenberg
  Hepatology Communications.2022; 6(6): 1457.     CrossRef
• Non-alcoholic fatty liver disease
  Rehab F. Abdel-Rahman
  Asian Pacific Journal of Tropical Biomedicine.2022; 12(3): 99.     CrossRef
• State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis
  Yongin Cho, Yong-ho Lee
  Endocrinology and Metabolism.2022; 37(1): 38.     CrossRef
• Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease
  Ji Hye Huh, Kwang Joon Kim, Seung Up Kim, Bong-Soo Cha, Byung-Wan Lee
  Hepatobiliary & Pancreatic Diseases International.2022; 21(3): 241.     CrossRef
• The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study
  Jiyun Park, Gyuri Kim, Bong-Sung Kim, Kyung-Do Han, So Yoon Kwon, So Hee Park, You-Bin Lee, Sang-Man Jin, Jae Hyeon Kim
  Cardiovascular Diabetology.2022;[Epub]     CrossRef
• Sociodemographic and genetic determinants of nonalcoholic fatty liver disease in type 2 diabetes mellitus patients
  Muhammad Adnan, Abdul Wajid, Wasif Noor, Andleeb Batool, Muhammad Aasim, Kamran Abbas, Quratul Ain
  Journal of Genetic Engineering and Biotechnology.2022; 20(1): 68.     CrossRef
• Concordance between indirect fibrosis and steatosis indices and their predictors in subjects with overweight/obesity
  Gaggini Melania, Vigna Luisella, Di Piazza Salvina, Gori Francesca, Tirelli Amedea Silvia, Bamonti Fabrizia, Maltinti Maristella, Napolitano Filomena, Chatzianagnostou Kyriazoula, Cristina Vassalle
  Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity.2022; 27(7): 2617.     CrossRef
• Stéatopathie métabolique hépatique évaluée par le FibroScan® avec contrôle des paramètres d’atténuation (CAP) chez la personne diabétique de type 2 en Côte d’Ivoire
  Jacko Abodo, Dimitri Kouamé, Jocelyne Danho, Moumouni Léilatou, Pierre Koffi-Dago, Adelaïde Hué, Assita Yao, Franck Kouassi, Anselme N’Guessan, Fulgence Bathaix
  Médecine des Maladies Métaboliques.2022; 16(6): 550.     CrossRef
• Non-invasive diagnosis and staging of non-alcoholic fatty liver disease
  Stergios Kechagias, Mattias Ekstedt, Christian Simonsson, Patrik Nasr
  Hormones.2022; 21(3): 349.     CrossRef
• Association between organochlorine pesticides and nonalcoholic fatty liver disease in the National Health and Nutrition Examination Survey 2003–2004
  Hyunji Sang, Kyu-Na Lee, Chang Hee Jung, Kyungdo Han, Eun Hee Koh
  Scientific Reports.2022;[Epub]     CrossRef
• Increased Risk of NAFLD in Adults with Glomerular Hyperfiltration: An 8-Year Cohort Study Based on 147,162 Koreans
  Dae-Jeong Koo, Mi Yeon Lee, Inha Jung, Sun Joon Moon, Hyemi Kwon, Eun-Jung Rhee, Cheol-Young Park, Won-Young Lee, Ki Won Oh, Se Eun Park
  Journal of Personalized Medicine.2022; 12(7): 1142.     CrossRef
• Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
  Da Hea Seo, Young Ju Suh, Yongin Cho, Seong Hee Ahn, Seongha Seo, Seongbin Hong, Yong-ho Lee, Young Ju Choi, Eunjig Lee, So Hun Kim
  Diabetes & Metabolism Journal.2022; 46(4): 630.     CrossRef
• New Insights into Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: The Liver-Heart Axis
  Georgiana-Diana Cazac, Cristina-Mihaela Lăcătușu, Cătălina Mihai, Elena-Daniela Grigorescu, Alina Onofriescu, Bogdan-Mircea Mihai
  Life.2022; 12(8): 1189.     CrossRef
• Efficacy and mechanism of Jiedu Tongluo Tiaogan Formula in treating type 2 diabetes mellitus combined with non-alcoholic fatty liver disease: Study protocol for a parallel-armed, randomized controlled trial
  Jinghan Xu, Chunli Piao, Yue Qu, Tianjiao Liu, Yuting Peng, Qi Li, Xiaohua Zhao, Pei Li, Xuemin Wu, Yawen Fan, Binqin Chen, Jie Yang
  Frontiers in Pharmacology.2022;[Epub]     CrossRef
• Ultrasound-Based Hepatic Elastography in Non-Alcoholic Fatty Liver Disease: Focus on Patients with Type 2 Diabetes
  Georgiana-Diana Cazac, Cristina-Mihaela Lăcătușu, Cătălina Mihai, Elena-Daniela Grigorescu, Alina Onofriescu, Bogdan-Mircea Mihai
  Biomedicines.2022; 10(10): 2375.     CrossRef
• Diosgenin Ameliorated Type II Diabetes-Associated Nonalcoholic Fatty Liver Disease through Inhibiting De Novo Lipogenesis and Improving Fatty Acid Oxidation and Mitochondrial Function in Rats
  Yujie Zhong, Zhiman Li, Ruyi Jin, Yanpeng Yao, Silan He, Min Lei, Xin Wang, Chao Shi, Li Gao, Xiaoli Peng
  Nutrients.2022; 14(23): 4994.     CrossRef
• The associations between changes in hepatic steatosis and heart failure and mortality: a nationwide cohort study
  Jiyun Park, Gyuri Kim, Hasung Kim, Jungkuk Lee, Sang-Man Jin, Jae Hyeon Kim
  Cardiovascular Diabetology.2022;[Epub]     CrossRef
• Association of Nonalcoholic Fatty Liver Disease with Coronary Artery Disease in Type 2 Diabetes Mellitus
  Neelakandan Ramya, Golepu Karthikeya, Sethu Prabhu Shankar
  Acta Medica International.2022; 9(1): 31.     CrossRef
• NAFLDin type 2 diabetes mellitus: Still many challenging questions
  Simona Cernea, Itamar Raz
  Diabetes/Metabolism Research and Reviews.2021;[Epub]     CrossRef
• The protective effect of shrimp cooked in different methods on high-cholesterol- induced fatty liver in rats
  Nora A. AlFaris, Ghedeir M. Alshammari, Jozaa Z. AlTamimi, Lujain A. AlMousa, Nora M. AlKehayez, Dalal H. Aljabryn, Reham I. Alagal, Mohammed A. Yahya
  Saudi Journal of Biological Sciences.2021; 28(1): 170.     CrossRef
• Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years
  Hye Won Lee, Jae Seung Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
  Journal of Diabetes and its Complications.2021; 35(1): 107747.     CrossRef
• Prognostic value of non-alcoholic fatty liver disease for predicting cardiovascular events in patients with diabetes mellitus with suspected coronary artery disease: a prospective cohort study
  Keishi Ichikawa, Toru Miyoshi, Kazuhiro Osawa, Takashi Miki, Hironobu Toda, Kentaro Ejiri, Masatoki Yoshida, Yusuke Nanba, Masashi Yoshida, Kazufumi Nakamura, Hiroshi Morita, Hiroshi Ito
  Cardiovascular Diabetology.2021;[Epub]     CrossRef
• Implications of Abdominal Adipose Tissue Distribution on Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: A Chinese General Population Study
  Chileka Chiyanika, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Henry Lik-Yuen Chan, Steve C. N. Hui, David K. W. Yeung, Winnie C. W. Chu
  Clinical and Translational Gastroenterology.2021; 12(2): e00300.     CrossRef
• Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: Diagnosis and Treatment
  Sook Jung Lee, Byung-Wan Lee
  The Journal of Korean Diabetes.2021; 22(1): 38.     CrossRef
• Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis
  Jingxuan Lian, Jianfang Fu
  Frontiers in Endocrinology.2021;[Epub]     CrossRef
• Allopurinol ameliorates high fructose diet induced hepatic steatosis in diabetic rats through modulation of lipid metabolism, inflammation, and ER stress pathway
  In-Jin Cho, Da-Hee Oh, Jin Yoo, You-Cheol Hwang, Kyu Jeung Ahn, Ho-Yeon Chung, Soung Won Jeong, Ju-Young Moon, Sang-Ho Lee, Sung-Jig Lim, In-Kyung Jeong
  Scientific Reports.2021;[Epub]     CrossRef
• Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate?
  Carolina M. Perdomo, Nuria Garcia-Fernandez, Javier Escalada
  Journal of Clinical Medicine.2021; 10(9): 2040.     CrossRef
• Fenofibrate, a PPARα agonist, reduces hepatic fat accumulation through the upregulation of TFEB-mediated lipophagy
  Jin Yoo, In-Kyung Jeong, Kyu Jeung Ahn, Ho Yeon Chung, You-Cheol Hwang
  Metabolism.2021; 120: 154798.     CrossRef
• Association Between Thyroid Hormone Levels and Advanced Liver Fibrosis in Patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease
  Jing Du, Sanbao Chai, Xin Zhao, Jianbin Sun, Xiaomei Zhang, Lili Huo
  Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 2399.     CrossRef
• Association between toothbrushing and non-alcoholic fatty liver disease
  Ji-Youn Kim, Yong-Moon Park, Gyu-Na Lee, Hyun Chul Song, Yu-Bae Ahn, Kyungdo Han, Seung-Hyun Ko, Houkai Li
  PLOS ONE.2021; 16(5): e0243686.     CrossRef
• Non‐alcoholic fatty liver disease and sarcopenia additively increase mortality: a Korean nationwide survey
  Joon Ho Moon, Bo Kyung Koo, Won Kim
  Journal of Cachexia, Sarcopenia and Muscle.2021; 12(4): 964.     CrossRef
• Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
  Won Euh, Soo Lim, Jin-Wook Kim
  Frontiers in Endocrinology.2021;[Epub]     CrossRef
• Modulation and bioinformatics screening of hepatic mRNA-lncRNAs (HML) network associated with insulin resistance in prediabetic and exercised mice
  Fatemeh Kazeminasab, Sayed Mohammad Marandi, Maryam Baharlooie, Mohammad Hossein Nasr-Esfahani, Kamran Ghaedi
  Nutrition & Metabolism.2021;[Epub]     CrossRef
• Liver Fibrosis Indices for the Prediction of Mortality in Korean Subjects: A 16-Year Prospective Cohort Study
  Tae Jung Oh, Kyuho Kim, Jae Hoon Moon, Sung Hee Choi, Nam H Cho, Hak Chul Jang
  Journal of the Endocrine Society.2021;[Epub]     CrossRef
• Non-Laboratory-Based Simple Screening Model for Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Developed Using Multi-Center Cohorts
  Jiwon Kim, Minyoung Lee, Soo Yeon Kim, Ji-Hye Kim, Ji Sun Nam, Sung Wan Chun, Se Eun Park, Kwang Joon Kim, Yong-ho Lee, Joo Young Nam, Eun Seok Kang
  Endocrinology and Metabolism.2021; 36(4): 823.     CrossRef
• The association of hepatic steatosis and fibrosis with heart failure and mortality
  Jiyun Park, Gyuri Kim, Hasung Kim, Jungkuk Lee, You-Bin Lee, Sang-Man Jin, Kyu Yeon Hur, Jae Hyeon Kim
  Cardiovascular Diabetology.2021;[Epub]     CrossRef
• Magnetic Resonance-Based Assessments Better Capture Pathophysiologic Profiles and Progression in Nonalcoholic Fatty Liver Disease
  Seung Joon Choi, Seong Min Kim, Yun Soo Kim, Oh Sang Kwon, Seung Kak Shin, Kyoung Kon Kim, Kiyoung Lee, Ie Byung Park, Cheol Soo Choi, Dong Hae Chung, Jaehun Jung, MunYoung Paek, Dae Ho Lee
  Diabetes & Metabolism Journal.2021; 45(5): 739.     CrossRef
• Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
  Eugene Han, Mi Kyung Kim, Byoung Kuk Jang, Hye Soon Kim
  Diabetes & Metabolism Journal.2021; 45(5): 698.     CrossRef
• The potential pathophysiological role of altered lipid metabolism and electronegative low-density lipoprotein (LDL) in non-alcoholic fatty liver disease and cardiovascular diseases
  Hüseyin Vural, Ferah Armutcu, Omer Akyol, Ralf Weiskirchen
  Clinica Chimica Acta.2021; 523: 374.     CrossRef
• Increased Visit-to-Visit Liver Enzyme Variability Is Associated with Incident Diabetes: A Community-Based 12-Year Prospective Cohort Study
  Kyuhoon Bang, Ji Eun Jun, In-Kyung Jeong, Kyu Jeung Ahn, Ho Yeon Chung, You-Cheol Hwang
  Diabetes & Metabolism Journal.2021; 45(6): 890.     CrossRef
• Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
  Yuan Zhu, Jiao Xu, Dong Zhang, Xingyu Mu, Yi Shi, Shangtao Chen, Zengxiang Wu, Shuangqing Li
  Frontiers in Endocrinology.2021;[Epub]     CrossRef
• Triglyceride Glucose-Waist Circumference Is Superior to the Homeostasis Model Assessment of Insulin Resistance in Identifying Nonalcoholic Fatty Liver Disease in Healthy Subjects
  Hwi Seung Kim, Yun Kyung Cho, Eun Hee Kim, Min Jung Lee, Chang Hee Jung, Joong-Yeol Park, Hong-Kyu Kim, Woo Je Lee
  Journal of Clinical Medicine.2021; 11(1): 41.     CrossRef
• The association between nonalcoholic fatty liver disease and esophageal, stomach, or colorectal cancer: National population-based cohort study
  Jung-Min Lee, Yong-Moon Park, Jae-Seung Yun, Yu-Bae Ahn, Kang-Moon Lee, Dae Bum Kim, Ji Min Lee, Kyungdo Han, Seung-Hyun Ko, Ming-Lung Yu
  PLOS ONE.2020; 15(1): e0226351.     CrossRef
• Non-alcoholic steatohepatitis and progression of carotid atherosclerosis in patients with type 2 diabetes: a Korean cohort study
  Hyeok-Hee Lee, Yongin Cho, Young Ju Choi, Byung Wook Huh, Byung-Wan Lee, Eun Seok Kang, Seok Won Park, Bong-Soo Cha, Eun Jig Lee, Yong-ho Lee, Kap Bum Huh
  Cardiovascular Diabetology.2020;[Epub]     CrossRef
• Visceral-to-Subcutaneous Abdominal Fat Ratio Is Associated with Nonalcoholic Fatty Liver Disease and Liver Fibrosis
  Chan-Hee Jung, Eun-Jung Rhee, Hyemi Kwon, Yoosoo Chang, Seungho Ryu, Won-Young Lee
  Endocrinology and Metabolism.2020; 35(1): 165.     CrossRef
• Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study
  Jun Hyung Kim, Jin Sil Moon, Seok Joon Byun, Jun Hyeok Lee, Dae Ryong Kang, Ki Chul Sung, Jang Young Kim, Ji Hye Huh
  Cardiovascular Diabetology.2020;[Epub]     CrossRef
• Non-invasive diagnosis of nonalcoholic fatty liver disease: impact of age and other risk factors
  Muharrem Bayrak
  The Aging Male.2020; 23(5): 1275.     CrossRef
• Establishment of a Risk Prediction Model for Non-alcoholic Fatty Liver Disease in Type 2 Diabetes
  Yali Zhang, Rong Shi, Liang Yu, Liping Ji, Min Li, Fan Hu
  Diabetes Therapy.2020; 11(9): 2057.     CrossRef
• Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease
  Dae Ho Lee
  Endocrinology and Metabolism.2020; 35(2): 243.     CrossRef
• Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
  Byung-Wan Lee, Yong-ho Lee, Cheol-Young Park, Eun-Jung Rhee, Won-Young Lee, Nan-Hee Kim, Kyung Mook Choi, Keun-Gyu Park, Yeon-Kyung Choi, Bong-Soo Cha, Dae Ho Lee
  Diabetes & Metabolism Journal.2020; 44(3): 382.     CrossRef
• Sarcopenia is associated with non-alcoholic fatty liver disease in men with type 2 diabetes
  D.H. Seo, Y.-h. Lee, S.W. Park, Y.J. Choi, B.W. Huh, E. Lee, K.B. Huh, S.H. Kim, B.-S. Cha
  Diabetes & Metabolism.2020; 46(5): 362.     CrossRef
• Pharmacological Strategies for Insulin Sensitivity in Obesity and Cancer: Thiazolidinediones and Metformin
  Luana A. Biondo, Alexandre A. S. Teixeira, Karen C. de O. S. Ferreira, Jose C. R. Neto
  Current Pharmaceutical Design.2020; 26(9): 932.     CrossRef
• Diabetes and Metabolism Journal in 2020: Good to Great
  In-Kyung Jeong
  Diabetes & Metabolism Journal.2020; 44(1): 1.     CrossRef
• Toll-like receptor 9, a possible blocker of non-alcoholic steatohepatitis?
  Soung Won Jeong
  Clinical and Molecular Hepatology.2020; 26(2): 185.     CrossRef
• The sex-specific effects of blood lead, mercury, and cadmium levels on hepatic steatosis and fibrosis: Korean nationwide cross-sectional study
  Seung Min Chung, Jun Sung Moon, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee
  Journal of Trace Elements in Medicine and Biology.2020; 62: 126601.     CrossRef
• Hepatic fibrosis is associated with total proteinuria in Korean patients with type 2 diabetes
  Eugene Han, Yongin Cho, Kyung-won Kim, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-wan Lee
  Medicine.2020; 99(33): e21038.     CrossRef
• Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping
  Zhipeng Liu, Yang Zhang, Sarah Graham, Xiaokun Wang, Defeng Cai, Menghao Huang, Roger Pique-Regi, Xiaocheng Charlie Dong, Y. Eugene Chen, Cristen Willer, Wanqing Liu
  Journal of Hepatology.2020; 73(2): 263.     CrossRef
• Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis
  Marieke de Vries, Jan Westerink, Karin H A H Kaasjager, Harold W de Valk
  The Journal of Clinical Endocrinology & Metabolism.2020; 105(12): 3842.     CrossRef
• Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
  Kyung-Soo Kim, Byung-Wan Lee
  Clinical and Molecular Hepatology.2020; 26(4): 430.     CrossRef
• Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective
  Eun-Jung Rhee
  Endocrinology and Metabolism.2019; 34(3): 226.     CrossRef
• Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease
  Anastasia Kontana, Konstantinos Tziomalos
  World Journal of Gastroenterology.2019; 25(28): 3664.     CrossRef

Citations

Citations to this article as recorded by  

• Heart failure and diabetes: Clinical significance and epidemiology of this two‐way association
  Terri Jerkins, Janet B. McGill, David S. H. Bell
  Diabetes, Obesity and Metabolism.2023; 25(S3): 3.     CrossRef
• Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose‐lowering medications
  David S. H. Bell, Edison Goncalves
  Diabetes, Obesity and Metabolism.2019; 21(6): 1277.     CrossRef

Citations

Citations to this article as recorded by  

• Association between lipids and apolipoproteins on type 2 diabetes risk; moderating effects of gender and polymorphisms; the ATTICA study
  Duane D. Mellor, Ekavi N. Georgousopoulou, Nathan M. D'Cunha, Nenad Naumovski, Christina Chrysohoou, Dimitrios Tousoulis, Christos Pitsavos, Demosthenes B. Panagiotakos
  Nutrition, Metabolism and Cardiovascular Diseases.2020; 30(5): 788.     CrossRef
• Effects of 7-Hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chromen-4 -one from Swietenia macrophylla King Seed on Oxidized LDL, HOMA Beta and Glucagon like Peptide 1 (GLP-1) Gene Expression in Type 2 Diabetic Rats
  Prasetyastuti ., Sunarti ., Ahmad Hamim Sadewa, Sri Mursiti, Mustofa .
  Asian Journal of Biochemistry.2017; 12(3): 85.     CrossRef

Citations

Citations to this article as recorded by  

• COVID-19-Induced Diabetes Mellitus: Comprehensive Cellular and Molecular Mechanistic Insights
  Praise Tatenda Nhau, Mlindeli Gamede, Ntethelelo Sibiya
  Pathophysiology.2024; 31(2): 197.     CrossRef
• Positive parental history of diabetes is associated with early diagnosis, better dietary compliance, and glycemic control among type 2 diabetes patients in southern Sri Lanka
  Warsha De Zoysa, Thilak Priyantha Weerarathna, Keddagoda Gamage Piyumi Wasana, Miyuru Kavinda Weerarathna, Vidarsha Senadeera
  Diabetology & Metabolic Syndrome.2024;[Epub]     CrossRef
• Effects of Propolis Consumption on Glycemic Indices and Liver Enzymes in Adults: A Grading of Recommendations Assessment, Development, and Valuation-assessed Systematic Review and Dose-Response Meta-analysis
  Shaghayegh Adeli, Mahsa Maroofi, Fatemeh Pourteymour Fard Tabrizi, Beitullah Alipour, Marzieh Heidari, Mahdi Vajdi, Mahdieh Abbasalizad-Farhangi
  Clinical Therapeutics.2024; 46(9): e6.     CrossRef
• Evolutionary algorithm for the optimization of meal intake and insulin administration in patients with type 2 diabetes
  Eva Gonzalez-Flo, Elaheh Kheirabadi, Carlos Rodriguez-Caso, Javier Macía
  Frontiers in Physiology.2023;[Epub]     CrossRef
• Role of Cytokines (IL-17 and IL-33), FGF-18, and WNT-5 in the Pathogenesis of Patients with Established Type II Diabetes
  Przha Mohammed, Kawa Amin
  Journal of Zankoy Sulaimani - Part A.2023; 25(2): 11.     CrossRef
• Cellular Chitchatting: Exploring the Role of Exosomes as Cardiovascular Risk Factors
  Giulia Germena, Laura Cecilia Zelarayán, Rabea Hinkel
  Frontiers in Cell and Developmental Biology.2022;[Epub]     CrossRef
• Combined associations of family history and self-management with age at diagnosis and cardiometabolic risk in 86,931 patients with type 2 diabetes: Joint Asia Diabetes Evaluation (JADE) Register from 11 countries
  Johnny T. K. Cheung, Eric Lau, Cyrus C. T. Tsui, Edmond L. N. Siu, Naomi K. W. Tse, Nicole Y. L. Hui, Ronald C. W. Ma, Alice P. S. Kong, Amy Fu, Vanessa Lau, Weiping Jia, Wayne H. H. Sheu, Leorino Sobrepena, K. H. Yoon, Alexander T. B. Tan, Yook-Chin Chia
  BMC Medicine.2022;[Epub]     CrossRef
• Capsaicin, its clinical significance in patients with painful diabetic neuropathy
  Phiwayinkosi V. Dludla, Bongani B. Nkambule, Ilenia Cirilli, Fabio Marcheggiani, Sihle E. Mabhida, Khanyisani Ziqubu, Yonela Ntamo, Babalwa Jack, Tawanda M. Nyambuya, Sidney Hanser, Sithandiwe E. Mazibuko-Mbeje
  Biomedicine & Pharmacotherapy.2022; 153: 113439.     CrossRef
• Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary
  Annamaria Mascolo, Raffaella Di Napoli, Nunzia Balzano, Donato Cappetta, Konrad Urbanek, Antonella De Angelis, Lucia Scisciola, Irene Di Meo, Maria Giuseppa Sullo, Concetta Rafaniello, Liberata Sportiello
  Frontiers in Cardiovascular Medicine.2022;[Epub]     CrossRef
• Impact of triglycerides and waist circumference on insulin resistance and β-cell function in non-diabetic first-degree relatives of type 2 diabetes
  Fahd Ahmed, Molham AL-Habori, Ebtesam Al-Zabedi, Riyadh Saif-Ali
  BMC Endocrine Disorders.2021;[Epub]     CrossRef
• Orientin Improves Substrate Utilization and the Expression of Major Genes Involved in Insulin Signaling and Energy Regulation in Cultured Insulin-Resistant Liver Cells
  Sithandiwe E. Mazibuko-Mbeje, Sinenhlanhla X. H. Mthembu, Andani Tshiitamune, Ndivhuwo Muvhulawa, Fikile T. Mthiyane, Khanyisani Ziqubu, Christo J. F. Muller, Phiwayinkosi V. Dludla
  Molecules.2021; 26(20): 6154.     CrossRef
• Identification of Pre-Diabetic Biomarkers in the Progression of Diabetes Mellitus
  Jae-Ho Lee, Do-Young Kim, Rubee Pantha, Eun-Ho Lee, Jae-Hoon Bae, Eugene Han, Dae-Kyu Song, Taeg Kyu Kwon, Seung-Soon Im
  Biomedicines.2021; 10(1): 72.     CrossRef
• Shared (epi)genomic background connecting neurodegenerative diseases and type 2 diabetes
  Valerio Caputo, Andrea Termine, Claudia Strafella, Emiliano Giardina, Raffaella Cascella
  World Journal of Diabetes.2020; 11(5): 155.     CrossRef
• Family history of diabetes in both parents is strongly associated with impaired residual β‐cell function in Japanese type 2 diabetes patients
  Minoru Iwata, Yutaka Kamura, Hisae Honoki, Kaori Kobayashi, Manabu Ishiki, Kunimasa Yagi, Yasuo Fukushima, Atsuko Takano, Hiromi Kato, Shihou Murakami, Kiyohiro Higuchi, Chikaaki Kobashi, Kazuhito Fukuda, Yukiko Koshimizu, Kazuyuki Tobe
  Journal of Diabetes Investigation.2020; 11(3): 564.     CrossRef
• The relationship between age of onset and risk factors including family history and life style in Korean population with type 2 diabetes mellitus
  Jin-Won Noh, Jin Hee Jung, Jeong Eun Park, Jung Hwa Lee, Kang Hee Sim, Jumin Park, Min Hee Kim, Ki-Bong Yoo
  Journal of Physical Therapy Science.2018; 30(2): 201.     CrossRef
• Clinical Characteristics of Subjects with Sulfonylurea-Dependent Type 2 Diabetes
  Se Hee Min, Soo Heon Kwak, Young Min Cho, Kyong Soo Park, Hye Seung Jung
  Endocrinology and Metabolism.2015; 30(4): 509.     CrossRef
• Nutritional Assessment of Type II Diabetic Patients
  El-Sayed H. Bakr
  Pakistan Journal of Nutrition.2015; 14(6): 308.     CrossRef